Open-angle glaucoma
Drug research and approvals for open-angle glaucoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 83 studies of open-angle glaucoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 8 authorised medicines for it.
- Recruiting worldwide: 83
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 8
Recruiting Now
Newest start dates first, of 83 recruiting on ClinicalTrials.gov ↗- Effect of Late Ripcord Removal From Glaucoma Drainage DeviceNCT07803536 · Not applicable · Duke University · starts Dec 1, 2026
- A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye…NCT07913074 · Phase 2 · Tavo Biotherapeutics · starts Oct 23, 2026
- Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma PatientsNCT07847073 · Phase 4 · Brett King · starts Oct 1, 2026
- REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular HypertensionNCT07675824 · Phase 1 / Phase 2 · Regeneron Pharmaceuticals · starts Sep 8, 2026
- A Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and DiseasesNCT07780890 · Not reported · Massachusetts General Hospital · starts Aug 18, 2026
- The Acute Effect of Exercise Type And Timing on Ambulatory Blood Pressure and Intra-Ocular Pressure in Individuals With…NCT07413614 · Not applicable · KU Leuven · starts Jul 31, 2026
- PEI-GT Trial for Initial Treatment of Primary Open-Angle Glaucoma With CataractNCT07700498 · Not applicable · Nanfang Hospital, Southern Medical University · starts Jul 15, 2026
- A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular HypertensionNCT07661329 · Phase 3 · YS Life Science Co., Ltd. · starts Jun 2, 2026
- iDose TR Administration in an Office-Based Surgery SettingNCT07816692 · Not reported · Glaukos Corporation · starts May 13, 2026
- Direct vs Standard SLT for Glaucoma: A Noninferiority TrialNCT07408154 · Not applicable · Medical University of South Carolina · starts Apr 27, 2026
Drug Pipeline
16 approved, 4 in phase 3, 7 in phase 2, 3 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Latanoprost, Timolol, Travoprost, Bimatoprost, Brimonidine, Brinzolamide, Dorzolamide, Tafluprost, Pilocarpine, Methazolamide, Betaxolol, Latanoprostene bunod, Netarsudil, Dapiprazole, Carteolol, Omidenepag isopropyl
- Trabodenoson
- Phase 3 Adenosine A1 receptor agonist
- Memantine
- Phase 3 Glutamate [NMDA] receptor negative allosteric modulator
- Ofloxacin
- Phase 3 Bacterial DNA gyrase inhibitor
- Citicoline
- Phase 3
- DE-104
- Phase 2 Rho-associated protein kinase inhibitor
- Anecortave acetate
- Phase 2 Unknown
- Mitomycin
- Phase 2 DNA inhibitor
- Ginkgo
- Phase 2
- Niacinamide
- Phase 2
- Pyruvate
- Phase 2
- Bimatoprost grenod
- Phase 2
- Ranibizumab
- Phase 1 Vascular endothelial growth factor A inhibitor
- Evodenoson
- Phase 1 Adenosine A2a receptor agonist
- Xelafaslatide
- Phase 1
How Its Trials Ended
860 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 195 whose ending is known, 53% met their primary endpoint, 1% missed it and 46% stopped early.
- Completed, result not reported45853%
- Ongoing10612%
- Met its primary endpoint10412%
- Status unknown10112%
- Stopped: other or unclear516%
- Stopped: enrollment or feasibility182%
- Stopped: sponsor or business decision162%
- Missed its primary endpoint20%
- Stopped: lack of efficacy20%
- Stopped: safety10%
- Stopped: funding10%
Medicines Authorised in the EU
Newest first| Jan 7, 2021 | RoclandaLatanoprost / netarsudil | Santen Oy | EMA ↗ |
| Nov 19, 2019 | RhokiinsaNetarsudil | Santen Oy | EMA ↗ |
| Jul 18, 2014 | SimbrinzaBrinzolamide;brimonidine tartrate | Novartis Europharm Limited | EMA ↗ |
| Feb 20, 2014 | IzbaTravoprost | Novartis Europharm Limited | EMA ↗ |
| May 19, 2006 | GanfortBimatoprost;timolol | AbbVie Deutschland GmbH & Co. KG | EMA ↗ |
| Apr 23, 2006 | DuoTravTravoprost;timolol | Novartis Europharm Limited | EMA ↗ |
| Mar 8, 2002 | LumiganBimatoprost | AbbVie Deutschland GmbH & Co. KG | EMA ↗ |
| Nov 27, 2001 | TravatanTravoprost | Novartis Europharm Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA